Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CGEN is 5.6 and suggests 181% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
Buy
Sell